Journal of Molecular Oncology Research

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Editorial - Journal of Molecular Oncology Research (2025) Volume 9, Issue 1

Revolutionizing cancer treatment: The synergy of ai-driven genomics and crispr-based oncogene editing

Ahana Bhat *

Department of Cancer Biology, University of Cambridge, UK

*Corresponding Author:
Ahana Bhat
Department of Cancer Biology, University of Cambridge, UK
E-mail: ahana@bhat.uk

Received: 01-Jan-2025, Manuscript No. AAMOR -25-161669; Editor assigned: 02-Jan-2025, PreQC No. AAMOR -25-161669(PQ); Reviewed: 18-Jan-2025, QC No. AAMOR -25-161669; Revised: 22-Jan-2025, Manuscript No. AAMOR -25-161669(R); Published: 29-Jan-2025, DOI: 10.35841/ aamor-9.1.272

Citation: : Bhat A. Revolutionizing cancer treatment: The synergy of ai-driven genomics and crispr-based oncogene editing. J Mol Oncol Res. 2025;9(1):272.

Visit for more related articles at Journal of Molecular Oncology Research

Introduction

Cancer remains one of the most challenging diseases to treat, requiring constant innovation in diagnostics and therapeutics. With the advent of artificial intelligence (AI) and gene-editing technologies like CRISPR, researchers are now exploring novel approaches to understanding and combating cancer at a molecular level. AI-driven cancer genomics and CRISPR-based oncogene editing represent two revolutionary advancements that, when combined, have the potential to redefine personalized medicine and targeted cancer therapy [1].

Artificial intelligence has significantly improved our ability to analyze vast genomic datasets. AI-driven tools use machine learning algorithms to identify genetic mutations associated with different cancer types, enabling early diagnosis and precision treatment. By analyzing tumor genomes, AI can detect biomarkers that predict treatment responses and disease progression. This predictive capability helps oncologists tailor therapies based on a patient’s genetic profile, reducing trial-and-error approaches in cancer treatment [2].

AI has also accelerated drug discovery by identifying potential anticancer compounds and optimizing drug combinations. Traditional drug development is a lengthy and costly process, but AI algorithms can analyze existing drugs and predict their effectiveness against specific cancer mutations. This approach shortens the time required to bring new treatments to clinical trials and increases the likelihood of successful therapies reaching patients [3].

CRISPR-Cas9 technology has transformed genetic engineering by allowing precise modifications to DNA. In cancer research, CRISPR is being utilized to edit oncogenes—genes that, when mutated, drive cancer progression. By targeting and modifying these oncogenes, scientists aim to deactivate cancer-promoting pathways and restore normal cellular function. This approach provides a promising alternative to traditional cancer treatments such as chemotherapy and radiation, which often cause severe side effects [4].

Unlike conventional treatments that affect both healthy and cancerous cells, CRISPR enables targeted gene editing with minimal off-target effects. Researchers have successfully used CRISPR to correct mutations in BRCA1 and TP53 genes commonly associated with breast and ovarian cancers. This precision not only improves treatment outcomes but also reduces toxicity, making it a safer option for patients [5].

AI and CRISPR are not just powerful independently; their integration holds even greater potential. AI can identify key genetic mutations and predict the most effective CRISPR-based interventions. By analyzing vast datasets, AI helps prioritize gene targets for editing, increasing the efficiency of CRISPR applications in oncology. This synergy can lead to more personalized and effective cancer treatments, improving patient outcomes [6].

Despite their promise, AI and CRISPR face several challenges in cancer research. AI models require extensive, high-quality datasets to make accurate predictions, and biases in genomic databases can impact results. Similarly, CRISPR editing needs further refinement to eliminate unintended genetic modifications. Ethical concerns surrounding gene editing also remain a topic of debate, requiring careful regulatory oversight to ensure responsible use [7].

Looking ahead, advancements in AI and CRISPR are expected to revolutionize cancer treatment further. AI-driven precision oncology will continue to improve, allowing real-time monitoring of cancer progression and treatment response. CRISPR technology is also evolving, with newer versions like CRISPR-Cas12 and Cas13 offering enhanced accuracy and safety for gene editing. The integration of these innovations will likely lead to groundbreaking therapies that can eradicate cancer at its genetic roots [8].

As AI and CRISPR become more prominent in cancer research, ethical considerations must be addressed. Issues such as genetic privacy, consent, and the potential for unintended consequences require strict regulatory frameworks. Collaborative efforts between scientists, policymakers, and bioethicists are essential to ensure that these technologies are used responsibly and equitably [9, 10].

Conclusion

The combination of AI-driven cancer genomics and CRISPR-based oncogene editing marks a new era in oncology. These technologies have the potential to enhance early detection, enable personalized treatments, and ultimately improve survival rates for cancer patients. While challenges remain, continued advancements and ethical oversight will ensure that these innovations pave the way for a future where cancer is no longer a devastating disease but a manageable condition with highly effective treatments.

References

  1. Abbaspour N. Fermentation's pivotal role in shaping the future of plant-based foods: An integrative review of fermentation processes and their impact on sensory and health benefits. Appl Food Res. 2024:100468.

    2. Indexed at, Google Scholar, Cross Ref

  2. Kaur H, Kaur G, Ali SA. Dairy-based probiotic-fermented functional foods: An update on their health-promoting properties. Ferme. 2022 Aug 27;8(9):425.

    3. Indexed at, Google Scholar, Cross Ref

  3. Rastogi YR, Thakur R, Thakur P, et al. Food fermentation–Significance to public health and sustainability challenges of modern diet and food systems. Intern J Food Micro. 2022;371:109666.

    4. Indexed at, Google Scholar, Cross Ref

  4. Mukherjee A, Breselge S, Dimidi E, et al. Fermented foods and gastrointestinal health: underlying mechanisms. Nat Rev Gastroen Hepato. 2024;21(4):248-66.

    5. Indexed at, Google Scholar, Cross Ref

  5. Marco ML, Sanders ME, Gänzle M, et al. The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on fermented foods. Nat Rev Gastroen Hepato 2021;18(3):196-208.

    6. Indexed at, Google Scholar, Cross Ref

  6. Teng TS, Chin YL, Chai KF, et al. Fermentation for future food systems: Precision fermentation can complement the scope and applications of traditional fermentation. EMBO. 2021;22(5):e52680.

    7. Google Scholar

  7. Gänzle MG, Monnin L, Zheng J, et al. Starter culture development and innovation for novel fermented foods. Anl Rev Food Sci Tech. 2023;15.

    8. Indexed at, Google Scholar, Cross Ref

  8. Sasi M, Kumar S, Hasan M, et al. Current trends in the development of soy-based foods containing probiotics and paving the path for soy-synbiotics. Crit Rev Food Sci Nutrin. 2023;63(29):9995-10013.

    9. Indexed at, Google Scholar, Cross Ref

  9. Grujovi? M?, Mladenovi? KG, Semedo?Lemsaddek T, et al. Advantages and disadvantages of non?starter lactic acid bacteria from traditional fermented foods: Potential use as starters or probiotics. Comprehensive Reviews in Food Science and Food Safety. 2022 Mar;21(2):1537-67.

    10. Indexed at, Google Scholar, Cross Ref

  10. Leeuwendaal NK, Stanton C, O’toole PW, et al. Fermented foods, health and the gut microbiome. Nutrients. 2022 Apr 6;14(7):1527.

    11. Indexed at, Google Scholar, Cross Ref

Get the App